CU23795A3 - Formulaciones líquidas de anticuerpo antirrábico - Google Patents

Formulaciones líquidas de anticuerpo antirrábico

Info

Publication number
CU23795A3
CU23795A3 CU20090099A CU20090099A CU23795A3 CU 23795 A3 CU23795 A3 CU 23795A3 CU 20090099 A CU20090099 A CU 20090099A CU 20090099 A CU20090099 A CU 20090099A CU 23795 A3 CU23795 A3 CU 23795A3
Authority
CU
Cuba
Prior art keywords
antibody
antirrabic
liquid formulations
formulations
rabies
Prior art date
Application number
CU20090099A
Other languages
English (en)
Inventor
Willem Egbert Marissen
Alexander Berthold Hendrik Bakker
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of CU23795A3 publication Critical patent/CU23795A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de anticuerpo, en particular formulaciones líquidas farmacéuticas que comprenden anticuerpos de virus de la rabia. Las formulaciones se pueden usar en la profilaxis post-exposición de la rabia
CU20090099A 2006-12-05 2009-06-04 Formulaciones líquidas de anticuerpo antirrábico CU23795A3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87289206P 2006-12-05 2006-12-05
EP06125400 2006-12-05

Publications (1)

Publication Number Publication Date
CU23795A3 true CU23795A3 (es) 2012-03-15

Family

ID=39092188

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090099A CU23795A3 (es) 2006-12-05 2009-06-04 Formulaciones líquidas de anticuerpo antirrábico

Country Status (13)

Country Link
US (1) US7959922B2 (es)
EP (1) EP2088997B1 (es)
JP (1) JP5410985B2 (es)
KR (1) KR101522036B1 (es)
CN (1) CN101557799B (es)
AU (1) AU2007328960B2 (es)
CA (1) CA2668947C (es)
CU (1) CU23795A3 (es)
EA (1) EA017549B1 (es)
IL (1) IL199004A (es)
MX (1) MX2009005414A (es)
WO (1) WO2008068246A1 (es)
ZA (1) ZA200902772B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
NZ580607A (en) * 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
AU2007328960B2 (en) 2006-12-05 2013-01-17 Crucell Holland B.V. Liquid anti-rabies antibody formulations
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
PE20142275A1 (es) * 2012-03-07 2015-01-08 Lilly Co Eli Formulacion de anticuerpo il-17
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JP7159642B2 (ja) * 2018-06-26 2022-10-25 東ソー株式会社 カラムの抗体に対する保持力の測定方法
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
JP2023529010A (ja) 2020-06-12 2023-07-06 ナンチン リーズ バイオラブス カンパニー，リミティド Ｔｎｆｒ２に結合する抗体およびその用途
CN114748618B (zh) * 2022-04-02 2024-07-19 重庆智翔金泰生物制药股份有限公司 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法
CN117771365B (zh) * 2023-12-07 2025-07-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒组合单克隆抗体制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE99958T1 (de) 1989-06-08 1994-01-15 Wistar Inst Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US20040013672A1 (en) 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
RU2292353C2 (ru) 2001-08-21 2007-01-27 Томас Джефферсон Юниверсити Рекомбинантные антитела и композиции, а также способы их создания и использования
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
WO2005023849A2 (en) 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
US7803914B2 (en) * 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
NZ580607A (en) 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
CN101166763B (zh) * 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
AU2007328960B2 (en) 2006-12-05 2013-01-17 Crucell Holland B.V. Liquid anti-rabies antibody formulations

Also Published As

Publication number Publication date
JP5410985B2 (ja) 2014-02-05
IL199004A (en) 2015-10-29
KR20090089881A (ko) 2009-08-24
KR101522036B1 (ko) 2015-05-20
MX2009005414A (es) 2009-06-01
EP2088997A1 (en) 2009-08-19
CN101557799B (zh) 2012-08-22
AU2007328960B2 (en) 2013-01-17
WO2008068246A1 (en) 2008-06-12
EA017549B1 (ru) 2013-01-30
CA2668947C (en) 2017-02-07
AU2007328960A1 (en) 2008-06-12
EA200970533A1 (ru) 2009-10-30
CN101557799A (zh) 2009-10-14
US7959922B2 (en) 2011-06-14
EP2088997B1 (en) 2016-08-24
JP2010511665A (ja) 2010-04-15
CA2668947A1 (en) 2008-06-12
IL199004A0 (en) 2010-02-17
ZA200902772B (en) 2012-09-26
US20100034829A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
CU23795A3 (es) Formulaciones líquidas de anticuerpo antirrábico
AR116860A2 (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EP2102238A4 (en) CD44 ANTIBODY
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CL2008003910A1 (es) Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida.
EP2501723A4 (en) HEPATITIS B-VIRUS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
EP1874351A4 (en) ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS, AND APPLICATIONS
CY2016030I1 (el) Αντισωματα εναντι της il-17
GT200900035A (es) Anticuerpo especifico prlr y sus usos
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
ECSP10010295A (es) Formulacion de anticuerpo
IL239023A0 (en) Neutralizing antibodies to influenza viruses
EP2011869A4 (en) NEW ANTI-CD98 ANTIBODY
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
CO5720212A1 (es) Composicion de anticuerpo her2
BR112012015721A2 (pt) modificação covalente de proteínas dirigida por ligante
BRPI0810851A2 (pt) Compostos de enxofre com inibidores da serina protease ns3 do vírus da hepatite c
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR10555A (es) Vacunas para malaria
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
EP2006379A4 (en) HIGH-FUNCTIONAL BIS-SPECIFIC ANTIBODY
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)